Alpha Tau is a private Israeli life sciences company focusing on the development and commercialization of a groundbreaking radiation therapy for the treatment and eradication of solid tumors.
Alpha Tau is the developer of a breakthrough alpha radiation cancer therapy intended to treat solid cancer tumors. The company’s therapy utilizes alpha radiation that treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha-emitting atoms into the tumor, enabling physicians to treat small tumors and metastatic lesions that has several significant clinical advantages.
Arc investment: 2018
Alpha Tau Announces the Publication of Exceptional Clinical Data from Alpha DaRT, its Novel Alpha Radiotherapy for Solid Tumors
/PRNewswire/ — Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a novel alpha radiation…